EP0858340A4 - COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY - Google Patents

COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY

Info

Publication number
EP0858340A4
EP0858340A4 EP96937097A EP96937097A EP0858340A4 EP 0858340 A4 EP0858340 A4 EP 0858340A4 EP 96937097 A EP96937097 A EP 96937097A EP 96937097 A EP96937097 A EP 96937097A EP 0858340 A4 EP0858340 A4 EP 0858340A4
Authority
EP
European Patent Office
Prior art keywords
obesity
combination therapy
treating diabetes
diabetes
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96937097A
Other languages
German (de)
French (fr)
Other versions
EP0858340A1 (en
Inventor
Roy G Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603724.7A external-priority patent/GB9603724D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0858340A1 publication Critical patent/EP0858340A1/en
Publication of EP0858340A4 publication Critical patent/EP0858340A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP96937097A 1995-11-01 1996-10-31 COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY Withdrawn EP0858340A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US713895P 1995-11-01 1995-11-01
US7138P 1995-11-01
GB9603724 1996-02-22
GBGB9603724.7A GB9603724D0 (en) 1996-02-22 1996-02-22 Combinatyion therapy for the treatment of diabebes and obesity
PCT/US1996/017444 WO1997016189A1 (en) 1995-11-01 1996-10-31 Combination therapy for the treatment of diabetes and obesity

Publications (2)

Publication Number Publication Date
EP0858340A1 EP0858340A1 (en) 1998-08-19
EP0858340A4 true EP0858340A4 (en) 1999-12-29

Family

ID=26308780

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96937097A Withdrawn EP0858340A4 (en) 1995-11-01 1996-10-31 COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY

Country Status (4)

Country Link
EP (1) EP0858340A4 (en)
JP (1) JPH11515027A (en)
AU (1) AU7484596A (en)
WO (1) WO1997016189A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
JP2000504318A (en) * 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー Obesity protein preparation
JP2001501177A (en) * 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Method of increasing individual sensitivity to OB protein by up-regulating OB protein receptor
CA2269660A1 (en) * 1996-10-31 1998-05-07 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
HUP0200092A3 (en) 1999-02-16 2003-02-28 Kaneka Corp Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active betha-3 agonist by the use of the same
JP2004331500A (en) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd Blood concentration control products
WO2003033468A1 (en) * 2001-10-17 2003-04-24 Kaneka Corporation PROCESS FOR PREPARATION OF (S)-α-HALOMETHYLPYRIDINE- METHANOL DERIVATIVES
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
GB0718415D0 (en) 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (en) * 1993-02-09 1994-08-17 Merck & Co. Inc. Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9716189A1 *

Also Published As

Publication number Publication date
AU7484596A (en) 1997-05-22
WO1997016189A1 (en) 1997-05-09
JPH11515027A (en) 1999-12-21
EP0858340A1 (en) 1998-08-19

Similar Documents

Publication Publication Date Title
ATA46794A (en) DEVICE FOR TREATING SKIN AREAS
DE69324625D1 (en) Device for the treatment of obesity and motor disorders of the stomach
DE69731736D1 (en) INJECTION TREATMENT FOR CONTROLLING MUSCLES AND RELATED PAIN
DE69836752D1 (en) PROSTAGLAND INAGONIST AND ITS USE FOR THE TREATMENT OF BONE DISEASES
FI964314A7 (en) Substituted sulfonamides as selective beta3-agonists for the treatment of diabetes and obesity
EP0998262A4 (en) ISOFLAVONOIDS FOR THE TREATMENT AND PREVENTION OF SKIN AGING AND SKIN WRINKLES
DE69739303D1 (en) DEVICE FOR THE THERMAL TREATMENT OF TISSUE
DE69739758D1 (en) VACCINE FOR THE TREATMENT OF LYMPHOMA AND LEUKEMIA
DE69609868D1 (en) NEW STEROIDESTERS FOR TREATING SKIN DISEASES
DE59410125D1 (en) DEVICE FOR PAIN THERAPY AND / OR INFLUENCING THE VEGETATIVE NERVOUS SYSTEM
DE69636674D1 (en) DEVICE FOR HEAT TREATMENT OF TISSUE
ATE527022T1 (en) USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT AND PREVENTION OF TUMORS, TUMOR-DEPENDENT DISEASES AND CACHEXIA
DE69830728D1 (en) MEDICAMENT FOR THE TREATMENT OF COMMON WATER AND HARN INCONTINENCE
DE69731515D1 (en) Device for the treatment of photosensitive material
DE69526390D1 (en) Spherical activated carbon for the treatment of ostomy peripheral inflammation
FI963252L (en) Novel opioid peptides for the treatment of pain and their use
DE69711311D1 (en) Device for the thermal treatment of tissue
ATE227127T1 (en) HIGH DOSE CHROME TRIPICOLINATE FOR THE TREATMENT OF TYPE II DIABETES
DE69630321D1 (en) DEVICE FOR LOCAL HEAT TREATMENT OF TISSUE
EP1043983A4 (en) TETRACYCLINE AND / OR TETRACYCLINE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF CEREBROVASCULAR DISEASES OF THE NERVOUS SYSTEM
DE69506019D1 (en) Pain treatment device
EP0795035A4 (en) Treatment of hides
DE69836209D1 (en) PREVENTION AND TREATMENT OF HEPATOCELLULAR CANCER
DE69620691D1 (en) Therapeutic agent for the treatment of hypercholesterolemia
EP0858340A4 (en) COMBINATION THERAPY FOR TREATING DIABETES AND OBESITY

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980602

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991115

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 31/44 A, 6A 61K 38/18 B, 6A 61K 38/17 B, 6A 61K 38/22 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010501